Industry News
-
Roche personalized cancer drug Rozlytrek nabs first approval
Japan is the first country to approve the drug, which targets patients with NTRK fusion-positive solid tumors, across 10 different tumor types
06/18/2019 -
Sanofi partners with Google on virtual healthcare innovation lab
The companies are seeking to transform how future medicines and health services are delivered by leveraging emerging data technologies.
06/18/2019 -
Pfizer bolsters cancer pipeline with $10B acquisition
Pfizer has agreed to buy Array Biopharma in a $10.64 billion cash deal.
06/17/2019 -
AstraZeneca invests in Korea biohealth
AstraZeneca has promised to invest $630 million into Korea’s biotech and healthcare sector over the next five years.
06/17/2019 -
Amgen, Lilly, Merck sue HHS
Amgen, Eli Lilly and Merck sued the Department of Health and Human Services in an attempt to block new rules requiring that drugmakers disclose the list price of their drugs in television ads
06/16/2019 -
Lannett to close Wyoming plant
Philadelphia-based Lannett announced it will close its Cody Laboratories subsidiary after failing to find a buyer.
06/14/2019 -
Novartis' secret settlement for kickbacks revealed accidentally
Confidential settlement talks over allegations that the company paid doctors to market drugs were revealed when a letter written to U.S. District Judge was accidentally filed in the court docket.
06/14/2019 -
JAMA study: Branded drug pricing trends
The Journal of the American Medical Association evaluated top-selling drugs finding that over a six year period, 78 percent of the drugs have seen an increase in costs by more than 50 percent.
06/13/2019 -
Catalyst sues FDA for approving rival drug
The drama surrounding rival treatments for a rare autoimmune disease is mounting.
06/12/2019 -
FDA slaps Indian manufacturer with an 10 observations
The FDA observations are piling up for one of India’s biggest generic drug manufacturers.
06/12/2019 -
Roche names new CEO of $13B diagnostics unit
Thomas Schinecker is filling the shoes of the retiring Michael Heuer, who was holding the position on an interim basis.
06/11/2019 -
FDA OKs Merck's Keytruda for head and neck cancer
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients.
06/11/2019 -
Roche wins accelerated approval for cancer treatment
The FDA grants accelerated approval to Roche’s drug combo for lymphoma.
06/10/2019 -
Merck to buy Tilos Therapeutics
Merck & Co. announced it was buying privately held biopharmaceutical company, Tilos Therapeutics, in a deal that could be valued at up to $773 million.
06/10/2019 -
Insys agrees to $225M opioid settlement
Insys Therapeutics has agreed to pay $225 million to settle the federal government's criminal and civil investigations into the company's marketing practices for its fentanyl-based medication, Subsys.
06/06/2019 -
Trump halts fetal-tissue research
The Trump administration announced that the federal government would sharply limit federal spending on medical research that uses tissue from aborted fetuses.
06/06/2019 -
Report: Pfizer passed on promising Alzheimer’s research
A few years ago, researchers inside Pfizer reportedly discovered that one of the company’s blockbuster drugs could be a breakthrough treatment for Alzheimer’s.
06/05/2019 -
Lilly scores big win with expanded approval for migraine treatment
For the first time ever, the FDA has approved a medication to treat cluster headaches.
06/05/2019 -
FDA expands Merck antibiotic indication to pneumonia treatment
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
06/04/2019 -
Bayer partners with Arvinas in $750M biotech deal
The German drugmaker will be providing an upfront payment, pharmaceutical R&D support and an investment $60 million
06/04/2019